Life Sciences M&A in 2026: Deals, Drivers and Synergy Targets

What Is Driving Pharma M&A Activity?

1. Lost exclusivity. PwC estimates more than $300 billion of branded pharma revenue is exposed to loss of exclusivity this decade. Merck expects biosimilar competition for Keytruda, which sold $31.7 billion in 2025, from 2028, and Bristol Myers Squibb lists 2028 US exclusivity dates for Eliquis and Opdivo.
2. Capacity to pay. EY puts the industry’s available firepower at a record $2.1 trillion.
3. A premium on de-risked assets. Since 2021, approved-stage biopharma targets have commanded a median $9.1 billion upfront, against $1.0 billion at Phase 1 and $226 million at discovery (J.P. Morgan). PwC sees buyers favouring assets with near-term clinical or commercial inflection points.
4. Licensing as the other route. Announced R&D licensing value reached $221.1 billion in January–September 2026 (J.P. Morgan), and EY found China took 34% of US and European biopharma alliance investment in 2025. Licensing gives buyers access to assets without acquiring the company — see our licensing deal tracker.
5. Portfolio reshaping. Thermo Fisher sold its microbiology business, BD combined its biosciences and diagnostics business with Waters, and Lonza agreed to sell its capsules and health ingredients business to become a pure-play CDMO. PwC notes that these carve-outs are creating new CDMO, CRO and bioprocessing platforms.

Biopharma M&A in 2026: The $1B+ Deals

Our 2026 log holds 44 acquisitions of drug companies worth $1 billion or more, each verified against the announcement. The largest by headline value:

By therapeutic area, the 44 deals split:

Every deal, with prices, premiums and CVRs, is in our pharma M&A tracker and the searchable pharma deals database.

Tools, Diagnostics, CDMO and Services Deals

Life sciences M&A extends well beyond drug companies. These are the 2026 deals of about $1 billion or more in tools, bioprocessing, diagnostics, contract manufacturing and services, each checked against the announcement.

Verified through 19 Oct 2026. Biopharma acquisitions are listed separately above.

Four themes stand out:

• Strategic platform deals. Merck KGaA is buying Bio-Techne to add proteomics, spatial biology and cell and gene therapy tools; Repligen is buying BioLife Solutions for cell therapy bioprocessing; Danaher is adding Masimo to its diagnostics segment.
• Carve-outs to private equity. Astorg bought Thermo Fisher’s microbiology business, Lone Star agreed to buy Lonza’s capsules and health ingredients business, and KKR agreed to take Integer, a medical device contract manufacturer, private.
• Peptide manufacturing. Samsung Biologics bid for PolyPeptide, CordenPharma agreed to buy peptide specialist AmbioPharm, and Siegfried agreed to buy three US and Australian drug-substance sites from SK Capital (the last two on undisclosed terms). DCAT links the peptide moves to demand driven by GLP-1 drugs.
• AI in diagnostics and services. Roche agreed to buy digital pathology company PathAI, and McKesson is acquiring Precision Medicine Group to expand its clinical research and commercialization services.

Synergy Capture: What Acquirers Are Promising

In several of the largest tools, diagnostics and bioprocessing deals, buyers put numbers on the synergies they expect. These are the targets announced for deals signed or completed in 2026:

What the announcements have in common:

• Cost synergies come first. Targets are set at year one to three and come from manufacturing, supply chain and SG&A (Waters) or from removing public-company costs and G&A (Repligen).
• Revenue synergies come later and are hedged. Waters and Danaher put theirs at year five; Repligen says its financial expectations assume only modest revenue synergies.
• Biopharma deals rest on the drugs. Sun Pharma’s announcement of the Organon acquisition, one of the largest biopharma deals in our log, refers to a “scope for synergies” without a number. In drug company acquisitions, value capture depends on development and launch execution more than on cost savings.

Deal Structures: Contingent Pay Is Common

27 of the 44 biopharma acquisitions of $1 billion or more in our log include contingent payments — contingent value rights or milestones tied to regulatory or commercial events. PwC also notes that buyers are relying more heavily on CVRs and milestone-based structures. Examples with CVRs:

• Gilead – Arcellx: $115/share cash + $5 CVR
• Eli Lilly – Centessa Pharmaceuticals: $38/share cash + CVR up to $9
• Biogen – Apellis Pharmaceuticals: $41/share cash + Syfovre sales CVR
• ARCHIMED – Esperion Therapeutics: $3.16/share cash + up to $100M CVR
• Eli Lilly – AtaiBeckley: $6.75/share cash + CVR up to $2.50
• Curium (CapVest) – Lantheus Holdings: $102.50/share cash + CVR up to $12

Contingent structures bridge valuation gaps when the asset’s value depends on an upcoming readout or launch. How CVRs and milestones are negotiated is covered in our term sheet guide.

What to Watch for the Rest of 2026

• Pending closings. Danaher expects to close Masimo in the second half of 2026; Samsung Biologics expects to complete PolyPeptide towards the end of 2026; KKR’s acquisition of Integer is expected by year-end; and Merck KGaA expects to close Bio-Techne by late 2026 or early 2027.
• Whether Q3 was a pause. The third-quarter drop in value followed a very strong second quarter; the patent cliff and firepower that drove the first half have not changed.
• More carve-outs. PwC says the new CDMO, CRO and bioprocessing platforms created by carve-outs could fuel further bolt-on deals in the second half.

Frequently Asked Questions

Methodology & Sources

The biopharma deal figures come from our 2026 log of acquisitions of drug companies or drug businesses with a headline value of $1 billion or more. The tools, diagnostics, CDMO and services table covers deals of about $1 billion or more announced in 2026 in those segments. Terms are as disclosed, and each deal links to the announcement or report it was checked against. Synergy targets are quoted from the companies’ announcements. Market totals come from the providers named and are not combined; Swiss franc values are ranked at an approximate dollar conversion.

Sources:

1. Vision Lifesciences research: our own deal tracking and insights from our day-to-day cross-border licensing and M&A advisory work (about us)
2. Company announcements for each deal, linked in the tables above
3. EY, Firepower M&A Report 2026: life sciences dealmaking
4. PwC, Pharmaceutical and life sciences: US Deals 2026 midyear outlook
5. J.P. Morgan, Q3 2026 Biopharma Licensing and Venture Report (DealForma data)
6. DealForma, Global Healthcare and Life Sciences – Q3 2026 Review
7. Merck & Co., 2025 Form 10-K (Keytruda exclusivity)
8. Merck & Co., full-year 2025 results (Keytruda sales)
9. Bristol Myers Squibb, 2025 Form 10-K (Eliquis and Opdivo exclusivity)
10. Waters, completion of combination with BD’s Biosciences & Diagnostic Solutions businesses (9 Feb 2026)
11. Waters, announcement of the BD combination (synergy targets)
12. Organon, Sun Pharma signs definitive agreement to acquire Organon
13. SK Capital Partners, agreement to sell Noramco, Extractas Biosciences and Purisys to Siegfried (27 Jan 2026)
14. CordenPharma, CordenPharma acquires AmbioPharm to expand global peptide API capacity (27 May 2026)
15. DCAT Value Chain Insights, CDMOs/CMOs: the key moves in 2026